Cara Therapeutics (Germany) Probability of Future Stock Price Finishing Under 5.87
| 69C Stock | EUR 4.84 0.00 0.00% |
Cara |
Cara Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cara Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cara Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cara Therapeutics is not yet fully synchronised with the market data | |
| Cara Therapeutics is way too risky over 90 days horizon | |
| Cara Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 23.03 M. Net Loss for the year was (88.44 M) with loss before overhead, payroll, taxes, and interest of (59.67 M). | |
| Cara Therapeutics has accumulated about 134.45 M in cash with (60.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Roughly 66.0% of the company shares are owned by institutions such as pension funds |
Cara Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cara Stock often depends not only on the future outlook of the current and potential Cara Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cara Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 53.5 M |
Cara Therapeutics Technical Analysis
Cara Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Cara Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cara Therapeutics. In general, you should focus on analyzing Cara Stock price patterns and their correlations with different microeconomic environments and drivers.
Cara Therapeutics Predictive Forecast Models
Cara Therapeutics' time-series forecasting models is one of many Cara Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cara Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Cara Therapeutics
Checking the ongoing alerts about Cara Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cara Therapeutics is not yet fully synchronised with the market data | |
| Cara Therapeutics is way too risky over 90 days horizon | |
| Cara Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 23.03 M. Net Loss for the year was (88.44 M) with loss before overhead, payroll, taxes, and interest of (59.67 M). | |
| Cara Therapeutics has accumulated about 134.45 M in cash with (60.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Roughly 66.0% of the company shares are owned by institutions such as pension funds |
Other Information on Investing in Cara Stock
Cara Therapeutics financial ratios help investors to determine whether Cara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cara with respect to the benefits of owning Cara Therapeutics security.